Bristol-Myers Squibb   4Q Revenues: $4.2 billion (-23%) 4Q Earnings: $924 million (-25%) YTD Revenues: $17.6 billion (-17%) YTD Earnings: $2.5 billion (-52%) Comments: U.S. sales decreased 38% to $2.2 billion in the quarter due to patent expirations for Avapro/Avalide in March 2012 and Plavix in May 2012. International sales were up 6% to $2.0 billion. Plavix sales were down 97% to $49 million. Avapro/Avalide sales were down 57% to $84 million. Abilify sales were up 11% to $819 million. Spry...